George Fennell and
M. Szostak, directors at
IDEXX Laboratories (IDXX), have sold portions of their holdings, a decision paralleled by
State of Alaska Department of Revenue and
Apollon Wealth Management LLC among others. Despite this, various investors like
COMGEST GLOBAL INVESTORS S.A.S.,
Vontobel Holding Ltd. and
Fiera Capital Corp have increased their positions.
IDEXX Laboratories has recently announced a promising
early detection test for Canine Lymphoma, and an aggressive
5M share buyback program. Analyst rating stand at a
Moderate buy, and Insider
Michael G Erickson exercised options worth $597K. Jim Cramer calls instead
IDEXX a
Safety Stock, and despite a decline in Q4, the overall outlook remains strong with
revenues consistently beating estimates, demonstrating a
strong financial performance and keeping the debt level
reasonably low. The company anticipates continued growth due to rising demand for pet healthcare and testing products, and
Piper Sandler increased the price target to
$510.00. Thus, despite various stakeholders' sell-offs, IDEXX Laboratories demonstrates a competent strategy and robust business operations.
Idexx Laboratories IDXX News Analytics from Tue, 06 Aug 2024 07:00:00 GMT to Sat, 15 Feb 2025 21:39:10 GMT -
Rating 3
- Innovation 7
- Information 8
- Rumor -4
